<DOC>
	<DOCNO>NCT01248494</DOCNO>
	<brief_summary>This open-label phase Ib multi-institution trial evaluate safety profile/tolerability preliminary anti-tumor effect BKM120 ( PI3K inhibitor ) endocrine therapy combination BEZ235 ( PI3K/ mTOR inhibitor ) endocrine therapy combination postmenopausal patient hormone receptor-positive metastatic breast cancer .</brief_summary>
	<brief_title>PhIb BKM120 BEZ235+Endocrine Treatment Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patients must provide informed write consent . Patients must &gt; /= 18 year age . ECOG performance status 01 . Clinical stage IV invasive mammary carcinoma , ERpositive and/or PRpositive immunohistochemistry ( IHC ) . Patients may either measurable nonmeasurable disease , allow . Patients whose breast cancer also HER2overexpressed ( IHC 3+ FISHpositive ) need previous treatment exposure trastuzumab ( Herceptin® ) Prior endocrine therapy ( ) allow . There limit line prior treatment metastatic setting . Patients must available tissue ( archive formalinfixed paraffin embed block ( FFPB ) fresh frozen tissue original diagnosis metastatic setting ) correlative study . Tissue need submit time registration . Patients able start study drug without tissue availability . Life expectancy &gt; /= 6 month Patients must adequate hematologic , hepatic , renal function . All test must obtain less 4 week study entry . This include : ANC &gt; /= 1500/mm3 Platelet count &gt; /= 100,000/mm3 HgB &gt; /= 9 g/dL Creatinine &lt; /= 1.5X upper limit normal INR &lt; /= 2Total serum bilirubin &lt; /= 1.5 x ULN ( patient know Gilbert Syndrome , total bilirubin &lt; /= 3.0 x ULN , direct bilirubin &lt; /= 1.5 x ULN ) AST ALT &lt; /= 3 x ULN ( &lt; /= 5.0 x ULN hepatic metastasis present ) Fasting plasma glucose ( FPG ) &lt; /= 140 mg/dL [ 7.8 mmol/L ] . For patient know diabetes , HgBA1c need &lt; /= 8 % Patients must able swallow retain oral medication . Postmenopausal female subject define prior protocol enrollment follow : Subjects least 55 year age Subjects 55 year age amenorrheic least 12 month folliclestimulating hormone ( FSH ) value &gt; /= 40 IU/L estradiol level &lt; /= 20 IU/L ; Prior bilateral oophorectomy Prior radiation castration amenorrhea least 6 month Current use LHRH agonist 12 month Patients may receive radiation therapy painful bone metastasis area impend bone fracture long radiation therapy complete &gt; /= 2 week prior study entry . Patients receive prior radiotherapy must recover toxicity ( &lt; /= grade 1 ) induce treatment Patients must diseasefree prior invasive cancer &gt; 5 year exception basal squamous cancer skin cervical carcinoma situ . Patients must complete screen assessment outline protocol . Locally recurrent resectable breast cancer . Any kind malabsorption syndrome significantly affect gastrointestinal function . Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , hormonal therapy , biologic therapy ) one specify protocol . Patients must discontinue cancer therapy 1 week prior first dose study medication , well recover toxicity ( &lt; /= grade 1 , except alopecia ) induce previous treatment . Any investigational drug discontinue 2 week prior first dose study medication . Prior therapy PI3K specific inhibitor . Prior use Akt mTOR inhibitor allow . Use drug ( prohibit concomitant medication ) Patients follow mood disorder judge Investigator psychiatrist : medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) &gt; /= CTCAE grade 3 anxiety Meets cutoff score &gt; /= 10 PHQ9 cutoff &gt; /= 15 GAD7 mood scale , respectively , selects positive response `` 1 , 2 , 3 '' question number 9 regard potential suicidal thought PHQ9 ( independent total score PHQ9 ) exclude study unless overrule psychiatric assessment Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic impairment lung function ( COPD &gt; grade 2 , lung condition require oxygen therapy ) symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1 2week period despite adequate medical support ) clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 , grade 3 ] QTcF &gt; /= 480 msec screen EKG known history QT/QTc prolongation Torsades de Pointes ( TdP ) ST depression elevation ≥ 1.5 mm 2 lead Diarrhea cause &gt; /= CTCAE grade 2 psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary patient symptomatic brain metastasis ( patient history brain metastasis must clinically stable 4 week completion radiation treatment 4 week steroid taper ) patient know history chronic liver renal failure patient know history chronic pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>